The Strange Case of Dr. Lucentis and Mr. Avastin. The Italian Competition Authority Fines Roche and Novartis for Collusion

European Competition Law Review, Vol. 35, No. 7, pp. 347-351, July 2014

11 Pages Posted: 4 Aug 2014

See all articles by Luca Arnaudo

Luca Arnaudo

Government of the Italian Republic (Italy) - Italian Competition Authority; Luiss Guido Carli University

Date Written: July 2014

Abstract

The article aims at retracing the main elements of an antitrust proceedings carried on by the Italian Competition Authority against the Roche and Novartis groups for an alleged infringement of article 101 TFEU. In the antitrust authority's view, as expressed in a formal decision adopted on March 2014, the cartel was set up in order to control the sales of two biotech pharmaceutical products, Avastin and Lucentis, within the Italian relevant market of the drugs used for curing vascular ocular diseases. The article details and discusses the decision, also providing further considerations concerning artificial product differentiation, off-label uses and human rights protection.

Keywords: Antitrust, Article 101 TFUE, Pharmaceutical industry, Product differentiation, Off-label uses

JEL Classification: K21, I11, L15

Suggested Citation

Arnaudo, Luca, The Strange Case of Dr. Lucentis and Mr. Avastin. The Italian Competition Authority Fines Roche and Novartis for Collusion (July 2014). European Competition Law Review, Vol. 35, No. 7, pp. 347-351, July 2014, Available at SSRN: https://ssrn.com/abstract=2428126 or http://dx.doi.org/10.2139/ssrn.2428126

Luca Arnaudo (Contact Author)

Government of the Italian Republic (Italy) - Italian Competition Authority ( email )

Piazza G. Verdi 6/a
Roma, 00184
Italy

Luiss Guido Carli University ( email )

Via O. Tommasini 1
Rome, Roma 00100
Italy

Do you have a job opening that you would like to promote on SSRN?

Paper statistics

Downloads
404
Abstract Views
1,801
rank
100,236
PlumX Metrics